Previous 10 | Next 10 |
Synthetic Biologics to Report 2020 Third Quarter Operational Highlights and Financial Results on November 10, 2020 -- Conference Call Scheduled for Tuesday, November 10, 2020 at 4:30 p.m. ET -- PR Newswire ROCKVILLE, Md., Nov. 3, 2020 ROCKVILLE, Md. , Nov. ...
Synthetic Biologics (SYN) plunges 42% premarket after announcing the results of a planned interim futility analysis of the investigator-sponsored Phase 2b clinical study of SYN-010 being conducted by Cedars-Sinai Medical Center ((CSMC)).It was concluded that although SYN-010 wa...
Synthetic Biologics Provides Update on Investigator-Sponsored Phase 2b Clinical Study of SYN-010 in IBS-C Patients PR Newswire ROCKVILLE, Md., Oct. 2, 2020 ROCKVILLE, Md. , Oct. 2, 2020 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), ...
Synthetic Biologics, Inc. (SYN) Q2 2020 Earnings Conference Call August 6, 2020, 04:30 PM ET Company Participants Vincent Perrone - Director, Corporate Communication Steven Shallcross - CEO, CFO, Treasurer and Secretary, Director Michael Kaleko - SVP of R&D Conference Call...
Synthetic Biologics (NYSEMKT: SYN ) : Q2 GAAP EPS of -$0.18 in-line. More news on: Synthetic Biologics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
ROCKVILLE, Md. , Aug. 6, 2020 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, t...
The FDA has signed off on a Phase 1 clinical trial evaluating ascending doses of Synthetic Biologics' ( SYN +7.4% ) SYN-020 in healthy volunteers. The study should launch in Q1 2021. More news on: Synthetic Biologics, Inc., Healthcare stocks news, Stocks on the move, Read more ... ...
ROCKVILLE, Md. , July 30, 2020 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need,&...
ROCKVILLE, Md. , July 29, 2020 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced ...
ROCKVILLE, Md. , June 30, 2020 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal ("GI") diseases in areas of high unmet need...
News, Short Squeeze, Breakout and More Instantly...
Synthetic Biologics Inc. Company Name:
SYN Stock Symbol:
NYSE Market:
Synthetic Biologics Inc. Website:
ROCKVILLE, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), (“Theriva” or the “Company”) is the new name of Synthetic Biologics, Inc. (NYSE American: SYN). The new name, logo and branding elements were introduced to better ref...
ROCKVILLE, Md., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced the presentation of new data from collaborators at Fund...
- The DSMC has reviewed the safety and pharmacokinetic data from Cohort 1 and recommended that the study may proceed to enroll patients into Cohort 2 - ROCKVILLE, Md., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical...